Drugs and Devices

FDA warns of counterfeit Avastin

On Feb. 14, the U.S. Food and Drug Administration notified healthcare professionals and patients about a counterfeit version of Avastin 400 mg/16mL, which may have been purchased and used by some medical practices in the United State. The counterfeit version of Avastin does not contain the medicine’s active ingredient, bevacizumab. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Newsletter Subscribe

  • This field is for validation purposes and should be left unchanged.

Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing

Shares